Alnylam Pharmaceuticals, Inc. (ALNY) › Analysis

Alnylam Pharmaceuticals (ALNY) stock analysis, November 20, 2026: Downtrend persists, breakout risk low

Published November 20, 2026 · ALNY chart, levels and live analysis

Alnylam Pharmaceuticals (ALNY) fell to $147.66 on November 20, hitting the 52‑week low and confirming a daily close below the breakout threshold of $147.66. The move follows a steep decline since the October 19 peak of $233.29, a drop of roughly 37%, and aligns with a bearish daily trend that mirrors the weekly downtrend. The balance of evidence points to a continued short‑term downside bias, with the structure holding below $150 and the math for a downside breakout offering more than a 5‑to‑1 reward‑to‑risk ratio.

Why it matters

The immediate catalyst was the release of third‑quarter results on October 29, which triggered a sharp sell‑off and prompted Pomerantz LLP to launch an investigation into possible securities‑fraud claims on November 19 PR Newswire. The legal inquiry added a layer of uncertainty to an already fragile price action, but the stock had already been under pressure from weaker than expected Amvuttra guidance presented at the Jefferies Global Healthcare Conference on November 18 Investing.com. The market’s reaction was swift: a 10.5% drop over five days left the stock well below its 40‑week average and the 50‑day simple moving average of $208.86.

Sector‑wide dynamics provided little cushion. The healthcare ETF XLV fell 5.4% over the same five‑day window, while the broader S&P 500 declined 7.2%, meaning ALNY underperformed both the market (‑23.0% versus SPY) and its sector (‑30.7% versus XLV) on a 50‑day basis. Volume was 75% below the 20‑day average, indicating that the sell‑off was not driven by a flood of new capital but rather by a decisive shift among existing holders.

Analysts remain divided. JPMorgan cut its price target to $254 from $369, citing a 2%‑21% reduction in Amvuttra revenue forecasts Investing.com. Truist downgraded the stock to hold and lowered its target to $225, also pointing to Amvuttra uncertainty Seeking Alpha. On the opposite side, a Benzinga piece highlighted the stock’s oversold RSI (27.9) and a $1 billion share‑repurchase program as potential upside triggers Benzinga. The consensus from 27 analysts still reads “buy” with a mean target of $285, but that target sits 48% above the current price, reflecting a wide valuation spread.

Overall, the news flow has not explained the full magnitude of the decline; the legal probe and Amvuttra guidance accounted for a portion, but the stock’s relative weakness versus both the market and its sector suggests that broader sentiment toward biotech and RNA‑i therapies remains cautious.

What the evidence says

The long‑term thesis that ALNY is in a downtrend remains intact. The price sits below its 40‑week average, the 52‑week low is now the current level, and the RSI is deep in oversold territory (27.9). The weekly trend is firmly down, and the structure holds below the round $150 level where sellers have historically stepped in on rallies.

For the next two to six weeks, the balance of evidence leans negative with high conviction. The daily trend runs with the weekly downtrend, the stock lags the S&P 500 by 23% over 50 days, and it also lags its own sector XLV by 31% over the same period. Breakout math shows a downside target of $125 (reward‑to‑risk 5.3) and a further target of $100 (reward‑to‑risk 11.1), with the stop set at $151.94. The only strong counter‑argument is the consensus “buy” rating and a mean price target of $285, but that target is far removed from current price action and does not alter the short‑term risk profile.

The most compelling case against a continued decline would be a rapid recovery in Amvuttra sales or a dismissal of the Pomerantz investigation, which could lift sentiment. Even if those events materialize, the stock would still need to clear the $150 resistance and then the swing‑zone level of $233.44 before the weekly trend could be considered reversed.

Levels that matter

The structure currently holds below the round $150 level, a price where sellers have repeatedly stepped in on short‑term rallies. Above that, the next structural barrier is the swing‑zone resistance at $233.44; a weekly close above that level would signal the end of the downtrend.

The breakout math is based on a daily close below $147.66, the 52‑week low. A move below that level triggers a stop at $151.94 (rounded $150 plus a quarter of the 14‑day ATR of $7.76). The downside targets are $125 and $100, delivering reward‑to‑risk ratios of 5.3 and 11.1 respectively. The math meets a 3‑to‑1 reward‑to‑risk threshold, making the downside case statistically attractive.

What would change the picture

A weekly close above the swing‑zone level of $233.44 would alter the picture, indicating that the weekly trend has ended. A non‑price catalyst such as a favorable resolution of the Pomerantz investigation or a materially better Amvuttra sales outlook would also shift sentiment.

What to watch

Get a message when the ALNY picture changes — the agent team watches the levels and the news for you.Create a free account

More ALNY analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.